SCHEMBL30748771

SCHEMBL30748771

C[C@@H]1CN(c2ccc(N3C(=O)C4(CCCCC4)c4c(Cl)nc(Cl)nc43)cn2)C[C@H](C)O1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.36
AOC3 Q16853 2/20 0.36
CCNE1 P24864 2/20 0.35
CDK2 P24941 2/20 0.35
RAB9A P51151 2/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CDK4 P11802 2/20 0.32
CCND1 P24385 2/20 0.32
TNKS O95271 1/20 0.32
PARP1 P09874 1/20 0.32
PARP10 Q53GL7 1/20 0.32
TNKS2 Q9H2K2 1/20 0.32
PARP2 Q9UGN5 1/20 0.32
ADRA1A P35348 1/20 0.32
HTR7 P34969 1/20 0.32
BTK Q06187 1/20 0.32
KCNH2 Q12809 1/20 0.32
CDK6 Q00534 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748824 0.97 KMT2A (0.37) KMT2AAOC3CCNE1CDK2RAB9A
SCHEMBL30748805 0.87 KMT2A (0.39) KMT2AAOC3CCNE1CDK2RAB9A
SCHEMBL31691225 0.85 AOC3 (0.32) AOC3CCNE1CDK2
SCHEMBL31691408 0.82 AOC3 (0.33) KMT2AAOC3
SCHEMBL30748871 0.81 AOC3 (0.37) AOC3CCNE1CDK2RAB9AMAPT
SCHEMBL30748800 0.79 AOC3 (0.38) AOC3CCNE1CDK2RAB9AMAPT
SCHEMBL30749062 0.77 KMT2A (0.39) KMT2AAOC3CCNE1CDK2RAB9A
SCHEMBL30749132 0.75 RAB9A (0.41) KMT2AAOC3CCNE1CDK2RAB9A
SCHEMBL31627091 0.75 SMO (0.33) AOC3CCNE1CDK2CDK4CCND1
SCHEMBL30748723 0.75 KMT2A (0.40) KMT2AAOC3RAB9AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT KMT2A 1604/4885AOC3 3013/4885CCNE1 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.